The GLP-1 receptor agonist liraglutide used to treat patients with type 2 diabetes (T2D) for 26 weeks had no impact on bone resorption, even though subjects lost weight.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.
There are 10 FDA-approved DPP-4 inhibitors--single agents and combination products. Do you speak their language? Find out with these 5 questions.
Trade names often mask the essential nature of a medication, but some of the new agents that treat type 2 diabetes take it to a new level. Here, 5 chances to see what you know.
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
The new guidelines signal a shift toward aggressive treatment for obesity as a primary disease and following with treatment for comorbidites that do not respond to weight loss.
The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.
Empagliflozin is the third sodium-glucose cotransporter 2 inhibitor approved for use in the US. There is a lot to learn about this new class. Here, 5 of the many things you need to know.